StockNews.AI
ABP
StockNews.AI
4 days

Abpro Announces Oral Presentation of First Preclinical Data for ABP-102/CT-P72, a Tetravalent Bispecific HER2 x CD3 T-Cell Engager, at AACR Annual Meeting 2025

1. ABP presents preclinical data for ABP-102/CT-P72 at AACR 2025. 2. ABP-102/CT-P72 targets HER2-overexpressing tumors while sparing normal tissues. 3. Exclusive collaboration with Celltrion advances ABP-102/CT-P72 development. 4. ABP focuses on life-threatening diseases through next-generation therapies.

4 mins saved
Full Article

FAQ

Why Bullish?

The presentation at AACR can attract investor interest, similar to previous biotech announcements that uplifted stock prices.

How important is it?

The presentation at a major oncology conference could significantly raise ABP’s visibility and market potential.

Why Short Term?

The upcoming presentation has immediate potential to influence investor sentiment and stock performance.

Related Companies

CelltrionHER2-targeted therapies
WOBURN, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq:ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and life-threatening diseases, today announced an oral presentation of preclinical data for ABP-102/CT-P72 at the American Association for Cancer ResearchⓇ Annual Meeting 2025 (“AACR 2025”) in the New Drugs on the Horizon session. AACR 2025 is taking place April 25-30, at the McCormick Place Convention Center in Chicago. Invited speaker presentation details Title:ABP-102/CT-P72: a novel HER2 x CD3 T cell engager with selective activity for HER2-overexpressing tumors and reduced activity on cells with normal HER2 expression levelsSession:New Drugs on the Horizon: Part 1Session Date:Sunday, April 27, 2025Session Time:1:00 pm to 2:30 pm CDTPresenter:Adam J. Pelzek, Ph.D., Associate Director, AbproAbstract & Data:Embargoed until time of presentation   About ABP-102/CT-P72ABP-102/CT-P72 an investigational HER2 x CD3 bispecific T-cell engager designed using Abpro’s proprietary DiversImmune® platform to selectively target HER2-overexpressing tumor cells while reducing activity in HER2-low expressing normal tissues. Its tetravalent IgG1-[L]-scFv format enables bivalent HER2 binding with functionally monovalent CD3 engagement and is designed to optimize tumor selectivity and reduce cytokine-related toxicity. Abpro has an exclusive collaboration with Celltrion, a leading South Korean biotechnology company ranked among the world’s top 25 by market capitalization, to advance ABP-102/CT-P72 in development for the treatment of HER2+ breast, gastric, pancreatic, colorectal, and other cancers. About AbproAbpro’s mission is to improve the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. Abpro is advancing a pipeline of next-generation antibody therapies, for HER2+ cancers, non-HER2+ gastric and liver cancer, and wet age-related macular degeneration and diabetic macular edema. These antibodies are developed using Abpro's proprietary DiversImmune® platform. Abpro is located in Woburn, Massachusetts. For more information, please visit www.abpro.co.

Related News